Firm intentionHealthcare9 November 2026

CorMedix Inc. to acquire substantially all assets of Heron Therapeutics, Inc.

Verified deal facts, source-backed narrative, and the Exit Mode founder lens for SME readers preparing to sell.

Deal facts

Buyer
CorMedix Inc.
Target
Substantially all assets of Heron Therapeutics, Inc.
Deal value
USD 222,600,000
Announced
9 November 2026
Status
Firm intention
Sector
Healthcare
Country
United States
Consideration
cash, shares, earn-out
What we know

CorMedix Inc. (Nasdaq: CRMD) and Heron Therapeutics, Inc. (Nasdaq: HRTX) announced on 9 November 2026 that they had entered into a definitive asset purchase agreement, signed on 8 November 2026. Under it, CorMedix will acquire substantially all of Heron's assets and assume certain of its liabilities. Excluded assets include Heron's federal income tax net operating loss carryforwards and certain other tax attributes. The assets include four commercial-stage products: ZYNRELEF (bupivacaine and meloxicam) for postoperative pain, APONVIE (aprepitant) for postoperative nausea and vomiting, and CINVANTI (aprepitant) and SUSTOL (granisetron) for chemotherapy-induced nausea and vomiting.

The upfront consideration is $145 million in cash, subject to customary purchase price adjustments, plus 14,583,333 shares of CorMedix common stock. Of the cash, $2.0 million goes into escrow with Citibank, N.A. to secure post-closing adjustments, which may not exceed $10.0 million in either direction. The share count was set by dividing $105 million by $7.20 per share and is fixed, so it does not move with CorMedix's share price before closing. Using CorMedix's $5.32 close on 6 November 2026, the companies value the stock at about $77.6 million and the upfront package at about $222.6 million. That aggregate is a market-price estimate, not a fixed sum.

Heron can also earn up to $55 million in contingent payments tied to calendar 2028 ZYNRELEF net sales: $25 million at $65 million or more, and a further $30 million at $95 million or more. In addition, Heron is due a 5% royalty on combined annual net sales of CINVANTI, SUSTOL and the products under its multi-product Development and License Agreement above $25 million in each of 2027, 2028 and 2029. Concurrently with signing, CorMedix entered into a new $150 million senior secured term loan facility with funds managed by Pharmakon Advisors and says it will draw $75 million of it to support the transaction. Heron intends to repay its Hercules working capital facility from proceeds, and Rubric Capital Management has agreed to exchange $35.0 million of Heron convertible notes due 2031, plus accrued interest, for CorMedix shares that Heron receives.

The deal needs approval from a majority of Heron's outstanding common stock and expiry or termination of the Hart-Scott-Rodino waiting period. Holders of about 22% of Heron's shares, including Rubric, have signed voting agreements in favour. There is no financing condition, and CorMedix expects closing in the first quarter of 2027. Heron owes CorMedix a $4.0 million termination fee in specified circumstances, such as terminating to accept a superior proposal. Heron says it will not liquidate and will remain a publicly traded company.

The archive tags include an earn-out. Compare completion cash, deferred payments and earn-outs before treating a headline amount as proceeds. Check the underlying announcement for the actual conditions; tags are not a complete payment schedule.

Deal timeline

1 update
  1. Firm intention

    CorMedix Inc. firm intention to acquire Heron Therapeutics, Inc.

    Item 1.01 Entry into a Material Definitive Agreement. Asset Purchase Agreement On November 8, 2026, Heron Therapeutics, Inc., a Delaware corporation (the “Company”), and CorMedix Inc., a Delaware corporation (the “Buyer”), entered into an Asset Purchase Agreement (the “Purchase Agreement”), pursuant to which the Company has agreed to sell substantially all of its assets to the Buyer, other than ce

    Source

For business owners

What would selling your own business involve?

Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.

Guides are free to read. Free tools require email access; indicative results are not professional advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

Similar deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

10 November 2026Firm intentionHealthcare

BioNTech US Inc. to acquire a Rare Pediatric Disease Priority Review Voucher from Scholar Rock Inc.

BioNTech US Inc. has agreed to buy a Rare Pediatric Disease Priority Review Voucher from Scholar Rock Inc. for $205 million in cash. Scholar Rock Inc. is a wholly owned…

Buyer
BioNTech US Inc.
Target
Rare Pediatric Disease Priority Review Voucher of Scholar Rock Inc.
Deal value
USD 205,000,000
Deal type
asset sale

Buyer history

CorMedix Inc.

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive